Mylan acquires Cold-EEZE brand to further expand OTC business
CANONSBURG — Mylan N.V. said Monday it is acquiring global rights to the Cold-EEZE brand cold remedy line from ProPhase Labs, Inc.
The Southpointe-based company said the 20-year old Cold-EEZE brand includes a family of leading over-the-counter cold remedies currently sold in the U.S. market, including zinc-based lozenges, gummies, oral sprays, capsules and oral liquid dose forms.
Mylan said that with strong brand recognition in the pharmacy and a growing and loyal customer base, Cold-EEZE will become its largest U.S. OTC brand franchise and further augment its growing U.S. OTC business.
“The acquisition of Cold-EEZE further builds upon our $1 billion global OTC business and helps us to enhance our presence in the U.S. OTC market,” said Mylan President Rajiv Malik.
Under the terms of the agreement, Mylan, through its U.S. OTC subsidiary, will purchase substantially all of the assets and other rights relating to the Cold-EEZE brand, including all U.S. businesses and U.S. and international trademarks. The closing of the proposed sale, expected to occur in the first quarter of 2017, is subject to approval of the shareholders of ProPhase Labs and other customary closing conditions.
Mylan’s global OTC business includes brands such as DonaT, Betadine, Saugella, ArmoLIPID, CB12, BrufenT, EndWarts, FrobenT, FerrogradT, MidNite and Vivarin.